Pricing Log in Create free account
Saturday 17 October 2026 Export SCNX’s income statement to Excel — free account

Scienture Holdings, Inc.

SCNX Healthcare Pharmaceutical Retailers

Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3,235.9%, EPS grew 85.4%, free cash flow fell 54.0% and total debt rose 831.4%, each against the same quarter a year earlier.

3.31 0.07 −2.07%
Market cap
$5.6M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
0.00%
F-score
5/9
Altman Z
5.42
Beneish M
−3.19
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 96.77%

Capital & Financial Ratios $m

Market Cap 5.55
Revenue 0.82
Net Income (39.95)
Free Cash Flow (14.44)
Net Debt 1.38
Current Ratio 3.04 (at or above 1.5: strong)
Debt/Equity 0.15 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.50) (negative: loss-making)
P/S ratio 159.66 (above 10: high)
P/B ratio 2.05
Past 5Y EPS Growth —
This Y EPS Growth 91.48% (at or above 15%: strong)
Next Y EPS Growth 100.00% (at or above 15%: strong)
Next Y revenue growth 1,009.59% (at or above 10%: strong)
Next 5Y EPS Growth 41.68% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 162×, against a ten-year median of 124×; over the ten years it ranged from 7.6× in 2022 to 4,680× in 2025.
P/S against its own 10 years 61.56%
10-year low 10-year high
P/B against its own 10 years 0.89%
10-year low 10-year high
EV/Sales against its own 10 years 61.70%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.00
Annual Dividend Yield 0.00%
total individual payouts
2024 17.50
8.00
8.00
1.50
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 0 0 7 8
Receivables 1 4 1 0
Inventory 0 — 0 0
Other — — — —
3 6 8 9
2023 2024 2025 Q'26
Payables 1 3 1 1
ST’ Debt — 0 — —
Other 2 1 1 0
12 8 3 3

Compound Annual Growth %

10y 5y 3y
Sales (17.38%) (52.10%) (65.21%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 74.56% 51.87% 489.15%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 — 1 0 0
’24 — 0 0 0 0
’23 0 0 0 0 1
’22 3 3 2 2 10
’21 3 2 3 2 10
’20 2 7 6 2 17
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (3) (2) (3) (5) (13)
’24 (10) 4 (5) (3) (14)
’23 (1) 0 (1) (1) (2)
’22 (1) (1) (1) 1 (2)
’21 (1) (1) (1) 0 (3)
’20 0 (4) 2 (1) (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (3) (2) (3) (5) (13)
’24 (13) 4 (5) (3) (14)
’23 (1) 0 (1) (1) (2)
’22 (1) (1) (1) 2 (2)
’21 (1) (1) (1) 0 (3)
’20 0 (4) 2 (1) (2)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.08) (0.07) — — —
’25 (0.33) (0.48) (0.19) (1.76) (2.70)
’24 16.77 (1.30) (1.34) (11.64) 2.48
’23 (1.05) (2.90) (1.49) (2.09) (7.49)
’22 (1.80) (1.95) (0.90) (1.50) (6.15)
’21 (1.20) (4.80) (2.40) (1.35) (9.75)
’20 0.30 (1.05) 0.30 (4.48) (4.93)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 1,035.00 495.00 495.00 776.25 1,503.75 840.00 105.00 94.13 92.25 11.53

Analyst estimates 2026–2028

Powerpack
High 18,000.00 2,250.00 2,250.00 3,600.00 4,350.00 4,057.50 1,301.25 492.50 1,114.00 160.18
People
People Employees 22 23 32 29 43 47 34 8 19 9
Revenue/emp, $m 0.11 0.13 0.12 0.26 0.40 0.21 0.30 0.17 0.01 0.05
Income, $m
Income, $m Revenue 2 3 4 7 17 10 10 1 0 0
Gross margin, % 100.00 100.00 88.28 65.50 33.33 47.99 53.85 3.59 4.39 76.81
EBT (1) 0 0 0 (3) (5) (2) (8) (19) (44)
EBT margin, % (47.27) 9.86 0.23 (3.82) (14.81) (53.75) (23.45) (622.00) (13,747.36) (10,080.42)
Net income (3) 0 0 0 (3) (5) (2) (8) (19) (44)
Depreciation 0 0 0 0 0 0 0 1 1 4
Per share, $
Per share, $ Revenue 7.08 8.25 10.69 18.80 33.31 18.22 18.15 1.79 0.04 0.03
Earnings (8.09) 0.90 0.03 (0.75) (4.79) (9.75) (6.15) (23.35) 2.69 (2.70)
Cash flow (1.44) 0.48 0.76 0.36 (4.31) (4.73) (2.77) (2.91) (4.23) (0.87)
Capex 0.00 0.00 (0.04) (0.21) (0.07) (0.04) 0.00 0.00 0.00 0.00
Free cash flow (1.44) 0.48 0.72 0.15 (4.38) (4.77) (2.77) (2.91) (4.23) (0.87)
Book value (3.27) (0.88) 2.36 10.47 16.89 6.95 0.61 0.71 23.43 4.57
Shares, m 0 0 0 0 1 1 1 1 3 15
Valuation, ×
Valuation, × P/E 0.00 1,244.93 26,785.71 0.00 0.00 0.00 0.00 0.00 56.15 0.00
P/S 146.25 122.73 63.17 131.63 59.55 48.57 6.10 74.93 2,055.03 403.62
P/B 0.00 0.00 286.56 236.43 117.48 127.39 182.25 188.39 6.46 2.79
EV/Sales 146.28 122.82 63.10 131.29 59.24 48.38 6.06 75.10 2,057.92 394.23
EV/FCF (721.02) 2,096.82 884.31 21,939.40 (450.36) (183.81) (39.70) (48.63) (30.38) (11.99)
Cash, $m
Cash, $m Operating cash flow (1) 0 0 0 (2) (3) (2) (2) (14) (13)
Capex — — 0 0 0 0 0 — 0 —
Free cash flow (1) 0 0 0 (2) (3) (2) (2) (14) (13)
Balance, $m
Balance, $m Working capital (1) 0 1 3 8 3 0 (9) (2) 5
Total debt 1 1 1 0 1 1 1 0 1 —
Net debt 1 0 0 (3) (5) (2) 0 0 1 (7)
Shareholders’ equity (1) 0 1 4 9 4 0 1 79 70
Returns, %
Returns, % ROA (233.43) 60.55 0.63 (7.29) (33.01) (68.33) (73.28) (219.71) 15.45 (43.92)
ROIC 0.00 144.75 (6.68) 4.95 (46.25) (174.44) 0.00 (484.54) (11.52) (41.95)
ROE 626.51 (39.59) 3.38 (11.41) (39.57) (85.40) (168.83) (4,031.09) 22.77 (55.65)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Scienture Holdings, Inc. vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HITI High Tide Inc. $228.2M — (loss-making) 92.0× +30.72% (above 0%: growing) +800.00% (above 0%: growing) −7.91% (below 0%: shrinking) 26.53% 4.38% Compare
PETS PetMed Express, Inc. $26.4M — (loss-making) 24.0× −19.86% (below 0%: shrinking) n/m +38.60% (above 0%: growing) 27.63% (15.19%) Compare
MEDS DataMeds AI, Inc $12.8M — (loss-making) — −77.15% (below 0%: shrinking) n/m −41.85% (below 0%: shrinking) 10.24% (412.67%) Compare
SCNX Scienture Holdings, Inc. $5.6M — (loss-making) — (loss-making) +3,235.92% (above 0%: growing) n/m −53.98% (below 0%: shrinking) 97.73% (785.71%)
POM Pomdoctor Limited - Sponsored ADR $5.0M — — — — — — — Compare
RDGT Ridgetech Inc. $3.0M — (loss-making) — (loss-making) +113.14% (above 0%: growing) n/m +4,848.31% (above 0%: growing) 22.81% 0.00% Compare
MDVLQ MedAvail Holdings, Inc. $2.9M — (loss-making) — (loss-making) −25.41% (below 0%: shrinking) n/m +66.32% (above 0%: growing) 43.95% (1,099.75%) Compare
BIMI BIMI Holdings Inc. $170.0K — (loss-making) — −48.85% (below 0%: shrinking) n/m +28.06% (above 0%: growing) 4.57% (124.83%) Compare
Median of peers $5.0M — — −22.63% — +33.33% 24.67% (70.01%)

All 8 Pharmaceutical Retailers stocks →

Scienture Holdings, Inc. (SCNX) key facts

  • Strength: Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024.
  • Scienture Holdings, Inc. (SCNX) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SCNX traded at $3.31, a market capitalization of $5.6 million.
  • Scienture Holdings, Inc. does not currently pay a dividend.
  • Return on equity was −55.7% and debt-to-equity 0.15.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.42 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Scienture Holdings, Inc. (SCNX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SCNX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com